Sodium Aescinate
Phase 1Small molecule
Sodium Aescinate is one of 46 small molecule programs targeting Low back pain. It is currently in Phase 1.
1
Indications
3
Total Trials
1
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
56 competitors in Low Back Pain
#DrugCompanyPhaseTrials
1Cymbalta
Jazz PharmaceuticalsApproved
Aleve
Jazz PharmaceuticalsApproved
Voltaren
NovartisApproved
Advil
KKenvue Brands
Approved
Lioresal
NovartisApproved
Toradol
RocheApproved
Celebrex
PPhiladelphia Eye Associates
Approved
Oxycontin
PProtega
Approved
Bayer Aspirin
BayerApproved
MS Contin
HHikma Pharmaceuticals LLC
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Intracerebral Hemorrhage1 trial
Reducing Edema After intraCerebral Hemorrhage
Unknown status·—·Phase 4·NCT05263167·300 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sodium Aescinate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- XXijing Hospital